stoxline Quote Chart Rank Option Currency Glossary
Sigilon Therapeutics, Inc. (SGTX)
22.47  -0.59 (-2.56%)    08-10 16:00
Open: 22.9
High: 23.0811
Volume: 81,878
Pre. Close: 23.06
Low: 22.085
Market Cap: 56(M)
Technical analysis
2023-09-01 4:49:48 PM
Short term     
Mid term     
Targets 6-month :  27.78 1-year :  32.44
Resists First :  23.78 Second :  27.78
Pivot price 22.2
Supports First :  21.82 Second :  20.61
MAs MA(5) :  22.46 MA(20) :  21.94
MA(100) :  12.4 MA(250) :  9.71
MACD MACD :  1.2 Signal :  1.6
%K %D K(14,3) :  58.1 D(3) :  58.4
RSI RSI(14): 71.2
52-week High :  28 Low :  3.76
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SGTX ] has closed below upper band by 40.1%. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 22.52 - 22.63 22.63 - 22.72
Low: 22.16 - 22.31 22.31 - 22.44
Close: 22.26 - 22.49 22.49 - 22.68
Company Description

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 17 Aug 2023
Hedge Fund and Insider Trading News: George Soros, Ray Dalio, Ken Griffin, Daniel Och, EDL Capital, Rokos Capital ... - Insider Monkey

Mon, 14 Aug 2023
Lilly Completes Acquisition of Sigilon Therapeutics | Eli Lilly and Company - Investors | Eli Lilly and Company

Fri, 21 Jul 2023
Inside the CVR of Lilly's Sigilon deal - BioCentury

Thu, 29 Jun 2023
Lilly to Acquire Sigilon Therapeutics - citybiz

Thu, 29 Jun 2023
Moderna (MRNA) Billionaire Afeyan Adds to Fortune as Sigilon Stock (SGTX) Soars - Bloomberg

Thu, 29 Jun 2023
Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 3 (M)
Shares Float 1 (M)
Held by Insiders 8.6 (%)
Held by Institutions 54.3 (%)
Shares Short 8 (K)
Shares Short P.Month 10 (K)
Stock Financials
EPS -14.83
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.97
Profit Margin -171.3 %
Operating Margin -174.7 %
Return on Assets (ttm) -23.7 %
Return on Equity (ttm) -76.4 %
Qtrly Rev. Growth 104.5 %
Gross Profit (p.s.) -9.88
Sales Per Share 7.05
EBITDA (p.s.) -11.84
Qtrly Earnings Growth 0 %
Operating Cash Flow -33 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -1.52
PEG Ratio 0
Price to Book value 2.04
Price to Sales 3.18
Price to Cash Flow -1.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android